InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative therapies that target the body's complement system, a critical component of the innate immune response. Its primary research and product development efforts focus on highly specific inhibitors of C5a and its receptor C5aR, molecules known to play a key role in driving harmful inflammatory processes. By leveraging proprietary anti-C5a and C5aR technologies, InflaRx aims to address acute, life-threatening, and chronic inflammatory diseases that currently have limited treatment options. The company’s lead programs include the development of monoclonal antibody drugs designed to control excessive inflammation at its source, underscoring its expertise in immunology and inflammation biology. InflaRx’s work has practical implications across several medical sectors, including infectious diseases and critical care, illustrated by the emergency use authorization granted by U.S. regulators for one of its investigational therapies for severe COVID-19 cases. As a result, InflaRx N.V. occupies an important position within the biopharmaceutical industry and the broader healthcare market, continually advancing new therapeutic avenues for complex immune-driven conditions.